OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IRD OPUS GENETICS INC

Pre-Mkt 12-18 07:55:34 EST

2.02

-0.12

-5.61%

High2.19	Low2.01	Vol483.64K
Open2.17	D1 Closing2.14	Amplitude8.18%
Mkt Cap139.31M	Tradable Cap127.51M	Total Shares68.96M
T/O995.52K	T/O Rate0.77%	Tradable Shares63.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":2.02,"timestamp":1766005200000,"preClose":2.14,"halted":0,"volume":483640,"delay":0,"floatShares":63122173,"shares":68964208,"eps":-1.373255,"marketStatus":"Pre-Mkt","change":-0.12,"latestTime":"12-18 07:55:34 EST","open":2.17,"high":2.185,"low":2.01,"amount":995520.9487000001,"amplitude":0.081776,"askPrice":2.1,"askSize":1453,"bidPrice":2,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.373255,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":2.02,"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.02,"latestTime":"19:10 EST","volume":1741,"amount":3513.813,"timestamp":1766016654054},"volumeRatio":1.131034843897941,"impliedVol":0.0018,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/IRD/tweets","defaultTab":"tweets","newsList":[{"id":"2592937687","title":"Opus Genetics Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937687?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:01","pubTimestamp":1765918871,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has granted an equity award to a new non-executive employee in the form of options to purchase 50,000 shares of the company's common stock. The options have an exercise price equal to the fair market value on the grant date and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in quarterly installments thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLc7rrhY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","BK4007","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","SG9999014013.SGD","SG9999014039.USD","BK4588","BK4139","LU2210150020.SGD","SG9999014021.USD","LU2095319765.USD","IRD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590542374","title":"Foundation Fighting Blindness Retinal Degeneration Fund Sells Common Shares of Opus Genetics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590542374","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590542374?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:36","pubTimestamp":1765492589,"startTime":"0","endTime":"0","summary":"Foundation Fighting Blindness Retinal Degeneration Fund reported a disposal of common shares of Opus Genetics Inc. , according to a recent SEC Form 4 filing. The form was filed by more than one reporting person, including Foundation Fighting Blindness Retinal Degeneration Fund and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7htR86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Foundation Fighting Blindness Retinal Degeneration Fund Sells Common Shares of Opus Genetics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2590518414","title":"Opus Genetics CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518414","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518414?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454413,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases, will present at the J.P. Morgan 2026 Healthcare Conference. The presentation, led by CEO George Magrath, M.D., is scheduled for Thursday, January 15, 2026, at 8:15 a.m. PT. A live and archived webcast of the presentation will be available on the company's website under the Investors section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLWtqWr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","BK4585","SG9999014039.USD","BK4007","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","IRD","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590582350","title":"Opus Genetics Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2590582350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590582350?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:43","pubTimestamp":1765370580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 07:43 ET (12:43 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RILY","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4127","BK4007","IRD"],"gpt_icon":0},{"id":"2590377862","title":"Opus Genetics Inc : B. Riley Initiates Coverage With Buy Rating; Price Target $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2590377862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590377862?lang=en_us&edition=fundamental","pubTime":"2025-12-10 11:58","pubTimestamp":1765339139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XF10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2590343187","title":"Opus Genetics Advances BEST1 Gene Therapy Trial After Positive Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343187","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343187?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281630,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has announced a positive recommendation from the Independent Data Monitoring Committee  to continue its Phase 1/2 clinical trial evaluating OPGx-BEST1, a gene therapy for Best disease. The recommendation follows a pre-specified safety review of one-month data from the sentinel participant, which demonstrated an initial favorable safety profile. Based on these results, the company will proceed with dosing the next four participants in the trial. No efficacy results have been presented at this stage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information conta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL12P2xG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","IRD","LU2095319765.USD","LU0314104364.USD","BK4139","SG9999014021.USD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","BK4585","LU2210150020.SGD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590343483","title":"Opus Genetics Announces Positive Recommendation From Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343483?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA28Z2QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2588578066","title":"Opus Genetics Grants Stock Options to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588578066","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588578066?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:01","pubTimestamp":1764709271,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has granted equity awards to two new non-executive employees under its 2021 Inducement Plan. The awards consist of options to purchase a total of 124,000 shares of the company's common stock. The options have an exercise price set at the fair market value on the grant date and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in quarterly installments. Vesting may accelerate or be forfeited based on certain events specified in the award agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6VGFJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","IRD","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2588066594","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588066594","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588066594?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:01","pubTimestamp":1764709260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA2MT1XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALUR","BBY","TITN","ZM","ADI","LIXT","LU2290526834.HKD","SPOT","SRPT","FCX","ESPR","BK4548","IE00BN0W2T93.GBP","LU1116320737.USD","VST","CDW","LU0784383803.USD","UPWK","PTCT","ZETA","ATAT","LU1815336760.USD","BK4541","DD","FLNC","FLY","SG9999000418.SGD","CDE","APD","SCCO","LU0323591593.USD","HL","LU1066051498.USD","FIBK","ANF","AMAT","SYM","IRD","KEYS","KSS","ABCB"],"gpt_icon":1},{"id":"2586479046","title":"Opus Genetics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479046","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479046?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:31","pubTimestamp":1764081060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:31 ET (14:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2586203134","title":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2586203134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586203134?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:03","pubTimestamp":1764072213,"startTime":"0","endTime":"0","summary":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage** Piper Sandler initiates coverage on Opus Genetics IRD.O with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  ** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease ** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG** As of last close, IRD stock is up ~68.1%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2586421831","title":"Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586421831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586421831?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:10","pubTimestamp":1764065412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Opus Genetics (IR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amgen-amgn-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amgen-amgn-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0128526141.USD","LU2242652126.USD","LU2112291526.USD","BK4585","LU0320765992.SGD","LU0122379950.USD","LU2242646821.SGD","BK4581","LU2089984988.USD","XLV","IRD","AMGN","LU1061106388.HKD","BK4007","LU0029874061.USD","LU2468319806.SGD","LU0289739699.SGD","IE0002141913.USD","LU1983299246.USD","BK4137","LU0109394709.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","IE0009355771.USD","LABU","BK4588","IE00B2B36J28.USD","BK4534","BK4566","LU1057294990.SGD","LU0868494617.USD","HCSG","XBI","LU0889565916.HKD","SG9999001440.SGD","BK4533"],"gpt_icon":0},{"id":"2586842896","title":"Opus Genetics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2586842896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586842896?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:34","pubTimestamp":1764059685,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10BO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2584312931","title":"Opus Genetics CEO to Speak at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584312931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584312931?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:00","pubTimestamp":1763643635,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will participate in the Piper Sandler 37th Annual Healthcare Conference. CEO George Magrath will join a fireside chat on December 2, 2025, at 10:00 a.m. ET in New York, NY.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL1WmzV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4585","BK4588","NDAQ","BK4112","LU2210150020.SGD","BK4007","LU2210149790.SGD","IRD","LU2095319765.USD","PIPR","IE00B3QW5Z07.USD","LU0314104364.USD","BK4127"],"gpt_icon":0},{"id":"2583930425","title":"Opus Genetics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583930425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583930425?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:52","pubTimestamp":1763041920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 08:52 ET (13:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2583564756","title":"Opus Genetics Inc - Initial Data From Trial Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564756?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5WBXNM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2583172564","title":"Opus Genetics Announces Dosing of First Participant in Opgx-Best1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2583172564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583172564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5WBXNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2582373073","title":"Opus Genetics reports third quarter results and raises $23 million in equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373073?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948888,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. reported cash and cash equivalents of $30.8 million as of September 30, 2025. After the quarter ended, the company raised approximately $23.0 million in gross proceeds through a registered direct equity offering, bringing its cash position to over $50 million. The company expects these funds to support operations into the second half of 2027. During the period, Opus Genetics advanced its pipeline, highlighted by positive clinical data in its OPGx-LCA5 Phase 1/2 trial and ongoing recruitment in the OPGx-BEST1 Phase 1/2 trial. The company also plans to submit a supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for presbyopia by year-end 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLHhMhR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","IRD","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4588","BK4007","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582373217","title":"Press Release: Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373217","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373217?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -. - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 -. - OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease -. - Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -. - Strengthened capital position from recent equity offering and non-dilutive funding from patient advocacy groups -. \"We have taken critical steps in advancing our pipeline, including the positive data and successful outcome of our recent FDA meeting regarding our LCA5 program and the opening of recruitment in our BEST1 Phase 1/2 clinical trial,\" said George Magrath, M.D., Chief Executive Officer, Opus Genetics. \"We look forward to continuing this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","IRD","ARB","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocuphire.com","stockEarnings":[{"period":"1week","weight":-0.192},{"period":"1month","weight":0.1609},{"period":"3month","weight":0.3557},{"period":"6month","weight":1.1261},{"period":"1year","weight":1.2159},{"period":"ytd","weight":0.6975}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.074201},{"month":2,"riseRate":0.47619,"avgChangeRate":0.057078},{"month":3,"riseRate":0.333333,"avgChangeRate":0.005763},{"month":4,"riseRate":0.4,"avgChangeRate":0.517227},{"month":5,"riseRate":0.619048,"avgChangeRate":4.359031},{"month":6,"riseRate":0.380952,"avgChangeRate":-0.018759},{"month":7,"riseRate":0.380952,"avgChangeRate":0.005385},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.018628},{"month":9,"riseRate":0.47619,"avgChangeRate":-0.005112},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.082285},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.065655},{"month":12,"riseRate":0.454545,"avgChangeRate":0.05454}],"exchange":"NASDAQ","name":"OPUS GENETICS INC","nameEN":"OPUS GENETICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OPUS GENETICS INC,IRD,OPUS GENETICS INC股票,OPUS GENETICS INC股票老虎,OPUS GENETICS INC股票老虎国际,OPUS GENETICS INC行情,OPUS GENETICS INC股票行情,OPUS GENETICS INC股价,OPUS GENETICS INC股市,OPUS GENETICS INC股票价格,OPUS GENETICS INC股票交易,OPUS GENETICS INC股票购买,OPUS GENETICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction